Comparative Pharmacology
Head-to-head clinical analysis: ATORVALIQ versus BAYCOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATORVALIQ versus BAYCOL.
ATORVALIQ vs BAYCOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATORVALIQ is a combination of atorvastatin and amlodipine. Atorvastatin is an HMG-CoA reductase inhibitor that decreases cholesterol synthesis in the liver. Amlodipine is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle, causing vasodilation.
Cerivastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing hepatic cholesterol production and increasing LDL receptor expression.
10-80 mg orally once daily. Starting dose 10-20 mg. Max dose 80 mg.
Cervastatin 0.4 mg orally once daily in the evening, with or without food.
None Documented
None Documented
The terminal elimination half-life of atorvastatin is approximately 14 hours; however, its active metabolites have a half-life of 20-30 hours, allowing for once-daily dosing.
2-4 hours (terminal elimination half-life); clinical context: supports twice-daily dosing
Atorvastatin is primarily eliminated via biliary/fecal excretion (approximately 70% as metabolites), with renal excretion accounting for less than 2% of the administered dose.
Renal: ~70% (mostly as unchanged drug); fecal: ~15%
Category C
Category C
Statin
Statin